Innovative Therapies Arrevus is developing advanced therapeutics targeting unmet medical needs in rare diseases like cystic fibrosis, oncology, and antimicrobial resistance, presenting opportunities for specialized medical product supplies and collaborative R&D support.

Growth Through Acquisition Since being acquired by Aceragen in 2021, Arrevus's integration into a larger biopharmaceutical portfolio signifies potential for expansion in sales channels, joint research initiatives, and clinical trial partnerships.

Funding and Grants With received grants totaling $1.1 million and ongoing funding efforts, there is a continuous need for advanced laboratory equipment, research services, and biotech supporting solutions to aid in their therapeutic development.

Clinical Progress Currently advancing a Phase III cystic fibrosis program and preclinical projects in infectious diseases, Arrevus offers opportunities for sales of clinical trial materials, lab reagents, and CRO services tailored to biotech research stages.

Market Focus Focusing on orphan and resistant infections, Arrevus targets niche markets with limited competitors, enabling partners to explore specialized diagnostics, personalized medicine tools, and biotech collaborations to accelerate treatment development.